For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 2,546 | |||
| General and administrative | 157,870 | |||
| Total operating expenses | 160,416 | |||
| Loss from operations | -160,416 | |||
| Net loss and comprehensive loss | -160,416 | |||
| Basic EPS | -0.78 | |||
| Diluted EPS | -0.78 | |||
| Basic Average Shares | 204,784,615 | |||
| Diluted Average Shares | 204,784,615 | |||
Semnur Pharmaceuticals, Inc. (SMNR)
Semnur Pharmaceuticals, Inc. (SMNR)